针对急性中风后四肢功能障碍的剂量效应关系:系统性审查和元分析
Xiaoxuan Wang1,2, Lu Xiao2,3, Lingyong Xiao1,2
1Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Frontiers in neurology
|March 14, 2024
概括
这项研究发现,针频率 (每隔一天或每天) 和短期治疗周期 (不到2周) 在急性中风患者中显著改善四肢功能障碍. 最佳的针保留时间仍未确定,需要进一步研究.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 综合医学是一个整体的医学.
背景情况:
- 急性中风通常导致肢体功能障碍,影响患者的康复和生活质量.
- 针是一种传统疗法,因其在中风康复中的潜力而受到探索.
- 优化针剂量对于最大限度地提高中风患者治疗效益至关重要.
研究的目的:
- 研究针与治疗急性中风四肢功能障碍的疗效之间的剂量反应关系.
- 为了确定最佳的针参数,包括频率,保留时间和疗程持续时间,用于中风康复.
主要方法:
- 对26项涉及1947名参与者的研究进行了系统审查和元分析.
- 搜索的数据库包括PubMed,Embase,Cochrane图书馆,CNKI,万芳,VIP和CBM直到2023年8月.
- 测量结果包括四肢功能障碍 (Fugl-Meyer评估),神经缺陷 (NIHSS) 和日常生活活动 (巴瑟尔指数,MBI,ADL).
主要成果:
- 低 (每隔一天) 和中度 (每天) 针频率显著改善了四肢功能障碍 (p < 0.00001).
- 短暂的针治疗疗程 (不到2周) 显示显著改善 (p < 0.00001).
- 在针保留时间方面没有发现显著差异,但注意到高异质性.
结论:
- 针在急性中风后改善四肢功能障碍方面是有效的.
- 最佳的针剂量包括低至中度的频率和短时间的治疗疗程.
- 需要进一步的高质量研究来确定最佳的针保留时间.
更多相关视频
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...